Headlands Research announced its research centers have been selected to participate in AstraZeneca’s upcoming Phase III COVID-19 vaccine trial. Headlands has built a position in the vaccine and infectious disease space, successfully conducting over 250 vaccine, prophylaxis and treatment trials to date across its North American sites.
Recruitment efforts for the AstraZeneca vaccine are actively underway at four of Headlands’ research sites, including: Atlanta, GA; McAllen, TX; Lake Charles, LA; and Palm Beach, FL. Headlands employs a diversity of traditional and non-traditional recruiting sources for its COVID-19 vaccine and treatment trials, with a strong focus on ensuring the inclusion of a wide array of ethnic and age groups.
“A vaccine for COVID-19 is crucial to overcome the current pandemic, and we appreciate the opportunity to work with AstraZeneca on this important Phase III trial,” said Mark Blumling, CEO of Headlands Research.